Drugs / Enamel Matrix Derivatives
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05442034 | Jan 2023 → Jun 2027 expected | periodontal disorder | Nova Southeastern University | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07059247 | Jul 2025 → Jul 2026 overdue | periodontitis, aggressive | Universidad Complutense de Madrid | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enamel matrix derivatives | “Enamel matrix derivatives (EMD) in combination with bone allograft.” NCT05442034 ↗ |
| Known as | EMD | “Enamel matrix derivatives (EMD) in combination with bone allograft.” NCT05442034 ↗ |
| Modality | Protein / enzyme biologic | “Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.” NCT05442034 ↗ |